Previous close | 387.88 |
Open | 385.57 |
Bid | 396.45 |
Ask | 399.95 |
Strike | 370.00 |
Expiry date | 2024-06-21 |
Day's range | 385.57 - 387.88 |
Contract range | N/A |
Volume | |
Open interest | 20 |
It's been a good week for Eli Lilly and Company ( NYSE:LLY ) shareholders, because the company has just released its...
The Danish pharmaceutical giant, which became Europe’s most valuable company last year, said Wegovy sales jumped 106% in the first quarter.
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Jyske Bank said the beat and upgrade were driven by a one-off U.S. sales adjustment, while underlying growth was a bit weaker than expected. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before Thursday's earnings, on the back of Wegovy's popularity.